Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03288025 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Pulmonary Arterial Hypertension Improvement With Nutrition and Exercise (PHINE)

StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study completion pushed from Jun 30, 2026 to Jun 30, 2027
    • Eligibility criteria expanded, about 17 words
    • Secondary endpoints: details revised at 1 of 1 entry
  2. Study completion date: Jun 30, 2025 to Jun 30, 2026v11
  3. Study completion date: Jun 30, 2024 to Jun 30, 2025v10
  4. Study completion date: Dec 18, 2023 to Jun 30, 2024v9
  5. Study completion date: Apr 18, 2023 to Dec 18, 2023v8
Show 6 earlier versionsHide 6 earlier versions
  1. Study completion date: Apr 18, 2022 to Apr 18, 2023v7
  2. Trial status: Recruiting to Active, Not Recruitingv6 Show 4 more changesShow less
    • Enrollment target: estimated 44 to confirmed 34
    • Primary completion date changed from estimate of Dec 28, 2022 to Feb 18, 2022
    • Study completion date: Dec 28, 2023 to Apr 18, 2022
    • Site details revised
  3. 3 versions Re-verified since Dec 13, 2018, no change to tracked fieldsv3-v5
  4. Start date changed from estimate of Sep 21, 2017 to Sep 27, 2017v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to investigate the extent to which diet and exercise may improve PAH through the modulation of insulin sensitivity. The central hypothesis is that dysregulated glucose metabolism elicits a response in PAH patients that can be modified by exercise and diet, thereby leading to improvements in pulmonary vascular disease.
Trial Details
NCT Number NCT03288025
Lead Sponsor The Cleveland Clinic
Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Conditions
(from sponsor)		 Pulmonary Arterial Hypertension, Insulin Resistance
Related terms Inflammation, Insulin Resistance, Pulmonary Arterial Hypertension
Enrollment 34 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov